Protherics PLC
2007 Annual General Meeting Results
London, UK; Brentwood, TN, US: 26 July 2007 - Protherics PLC ("Protherics" or
the "Company"), the international biopharmaceutical company focused on critical
care and cancer, is pleased to announce that Resolutions 1 to 11, 13 and 14 were
duly passed at its Annual General Meeting held earlier today. Since Resolution
11 was passed, Resolution 12 was withdrawn.
Details of the resolutions passed together with proxy figures are set out below
and will shortly be displayed on the Company's website www.protherics.com.
Copies of the resolutions have been filed with the United Kingdom Listing
Authority's Document Viewing Facility and are available from:
The Financial Services Authority
25 The North Colonnade
Canary Wharf
London
E14 5HS
RESOLUTIONS No. of proxy For Against Withheld
Votes received
1 To receive the financial statements for 214,211,771 213,984,886 224,562 2,323
the year ended 31 March 2007 together
with the reports of the Directors and
Auditors thereon
2 To re-elect John Robert Brown as a 214,211,771 214,167,686 37,904 6,181
Director
3 To re-elect Garry Watts as a Director. 214,211,771 214,155,056 47,135 9,580
4 To elect Jacques Gonella as a Director. 214,211,771 200,333,427 13,868,764 9,580
5 To elect Saul Komisar as a Director. 214,211,771 214,009,993 30,994 170,784
6 To reappoint KMPG Audit Plc as Auditors 214,211,771 213,855,392 335,479 20,900
of the Company.
7 To authorise the Directors to set the 214,211,771 214,162,266 43,640 5,865
remuneration of the Auditors
8 To approve the Directors' Remuneration 214,211,771 203,113,734 387,777 10,710,260
Report for the year ended 31 March 2007.
9 To increase the existing authorised share 214,211,771 214,138,538 64,571 8,662
capital of the Company from £9,500,000 to
£9,700,000 by the creation of 10,000,000
ordinary shares of 2p each.
10 To authorise the Directors to allot 214,211,771 214,073,118 86,394 52,259
shares pursuant to section 80 of the
Companies Act 1985.
11 To authorise the Directors to dis-apply 214,211,771 197,281,492 16,751,619 178,660
pre-emption rights pursuant to section 95
of the Companies Act 1985 (in relation to
up 10% of issued share capital).
12 To authorise the Directors to dis-apply Resolution 12 was withdrawn following the passing of
pre-emption rights pursuant to section 95 Resolution 11
of the Companies Act 1985 (in relation to
up to 5% of issued share capital).
13 To amend Article 98 of the Company's 214,211,771 213,982,824 156,327 72,620
Articles of Association to increase the
maximum aggregate amount of fees that may
be paid to directors from £200,000 to
£400,000.
14 To approve an amendment to the Protherics 214,211,771 214,001,952 136,705 73,114
PLC 2005 Deferred Bonus Plan to allow
Deferred Awards to be granted with a
value of up to 75% of annual basic
salary.
| Ends |
For further information please contact:
Protherics
Nick Staples, Director of Corporate Affairs +44 (0) 7919 480510
Julie Vickers, Company Secretary +44 (0)1928 518010
Financial Dynamics - press enquiries
London: Ben Atwell, Anna Keeble +44 (0) 20 7831 3113
New York: John Capodanno, Jonathan Birt +1 212 850 5600
Or visit www.protherics.com
This information is provided by RNS
The company news service from the London Stock Exchange
Protherics PLC announces AGM Results
| Source: Protherics PLC
Cheshire, UK--(Marketwire - July 26, 2007) -